Science Sparks @ ACTREC
13 July 2026Publications
- 1. Tanwar KS, Sawant VV, Rawat D, Dubey V, Shaikh AW, Dwivedi P, Dev I, Choudhury S, Agrawal A (2026). Radiolabeling and physicochemical characterization of terbium-161 DOTATATE. Nuclear Medicine Communications.
- 2. Punde R, Kshirsagar D, Shinde P, Darekar K, Chaudhari L, Laskar S (2026). Evaluation of revised TRS398 dosimetry protocol for pencil beam scanning proton therapy systems. Biomedical Physics & Engineering Express. 12(4).
- 3. Sridhar K, Moiyadi A, Balasubramaniam A, Panikar D, Muzumdar D (2026). Pre surgical evaluation of high grade gliomas in the Asia Pacific region: a pragmatic resource stratified framework. Journal of Clinical Neuroscience. 152:112188.
- 4. Saha P, Malu P, Joshi P, Hole A, Chaturvedi P, Vahanwala S, Krishna CM (2026). Raman spectroscopy of biofluids: fusion strategies for detecting oral potentially malignant disorders and oral Cancers. Applied Spectroscopy.
- 5. Gala RM, Prasad M, Srinivasan S, Gollamudi VRM, Dhamne C, Moulik NR, Parambil B, Chichra A, Narula G, Chinnaswamy G (2026). Nutritional status at diagnosis and follow-up and its impact on short-term clinical outcome in children with cancer: a real-world report from India. Ecancermedicalscience. 20:2137.
- 6. Ambekar T, Oak A, Kannusamy S, Cheulkar S, John RR, Chavan S, Mendhe S, Kadam S, Lade M, Balasubramanium G, Desouza A, Saklani A, Dikshit R, Chaturvedi P, Gupta S (2026). A hospital-based study of survival in colon cancer patients of Tata Memorial Hospital (Mumbai). Ecancermedicalscience. 20:2123.
- 7. Coupland SE, Rao A, Jonigk D, Bülow R, Chetty R, Rane SU, Dave S, Naresh KN (2026) . Promise and pragmatism of AI in global-scale digital pathology: pan-cancer approaches for clinical practice. Journal of Clinical Pathology.
- 8. Jobanputra K, Dhanawat A, Prakash G, Arora A, Dey S, Pawar A, Jadhav B, Menon N, Shah M, Pal M, Bakshi G, Murthy V, Maitre P, Popat P, Sable N, Ringe-Katdare A, Agrawal A, Menon S, Noronha V, Prabhash K, Joshi A (2026). Prognostic Reclassification and Survival Outcomes in Intermediate-Risk and Poor-Risk Nonseminomatous Germ Cell Tumors: Single-Institution Experience From Western India. JCO Global Oncology. 12(7):e2500695.
- 9. Mandal G, Biswas S, Anadon CM, Tamuli B, Chaurio RA, Lopez-Bailon LU, Plappert N, Carrion-Estrada D, Mine JA, Lai C-H, Moreno AP, Johnson J, Moran-Segura CM, Fang B, Marchion D, Chaudhary N, Terry KL, Sasamoto N, Townsend MK, O’Brien J, Antonia SJ, Tworoger SS, Yu X, Rodriguez PC, Conejo-Garcia JR (2026). Isotype-switched antibodies originating from tertiary lymphoid structures can antagonize ovarian cancer progression,iScience. 29(8):116757 Thesis
Girish Chandra Panigrahi. 2026. To evaluate the druggability of mitochondrial redox for targeting therapy resistant non-small cell lung cancer using mitocurcumin (LIFE09201904005) (Guide: Dr Vikram Gota)
Video of the Week
Next-Generation Treatment Pathways in Prostate Cancer
Upcoming Events
July 17, 2026
At ACTREC, Tata Memorial Centre, Kharghar
July 24, 2026
At ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai
Do You Know?
In 2020, FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for people with unresectable pleural mesothelioma who have not received other treatments.
Cancer News
EurekAlert, 09/07/2026
The best-known examples are mutations in the BRCA1 and BRCA2 genes, which greatly increase the risk of developing certain cancers, including breast, ovarian, pancreatic and prostate cancer. Genetic testing for BRCA mutations has transformed cancer care, helping people at risk access early screening...
MedicalXpress, 08/07/2026
The study evaluated outcomes from the Double Lung Transplant Registry for Lung-Limited Malignancies—known as the DREAM registry a pioneering Northwestern Medicine program designed to test whether replacing lungs overtaken by treatment-resistant cancer can remove organ-confined...
Sciencedaily, 07/07/2026
Scientists at the University of Illinois Chicago have turned an unlikely source into a potential new weapon against cancer: bacteria that naturally live inside tumors. They developed a peptide called aurB, inspired by a bacterial protein, that infiltrates cancer cells and effectively cuts off their energy supply by targeting...
© 2026 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)